首页> 外文期刊>Diabetes care >Abnormal glomerular permeability characteristics in diabetic nephropathy: implications for the therapeutic use of low-molecular weight heparin.
【24h】

Abnormal glomerular permeability characteristics in diabetic nephropathy: implications for the therapeutic use of low-molecular weight heparin.

机译:糖尿病肾病中肾小球通透性异常:对低分子量肝素的治疗用途的意义。

获取原文
获取原文并翻译 | 示例
           

摘要

The physicochemical characteristics of the glomerular capillary filtration membrane restrict the passage of macromolecules on the basis of molecular weight, charge, and shape. The proposed ionic charge permselectivity characteristics of the glomerular basement membrane (GBM) are determined by its chemical composition, primarily the highly sulfated glycosaminoglycan heparan. In diabetic nephropathy, the heparan sulfate content of the GBM is diminished. It has been proposed that decreased GBM heparan sulfate content causes decreased permselectivity to negatively charged macromolecules such as albumin, allowing this protein to leak into the urinary space. One possible explanation for decreased GBM heparan sulfate content in diabetic nephropathy is the observation that heparanase, an enzyme capable of degrading heparan sulfate, is upregulated in the glomerular epithelial cell (GEC) in response to increased glucose. Increased GEC heparanase activity has been demonstrated in glomeruli in diabetic kidneys, and increased urine heparanase has been observed in diabetic nephropathy. In vitro studies have shown that GEC heparanase activity depends on the glucose concentration of the culture medium. GEC heparanase activity can be inhibited by heparin compounds. Sulodexide, an orally active low-molecular weight heparin, has been shown to lower urine albumin excretion. The working hypothesis that has emerged is that sulodexide may be an in vivo heparanase inhibitor that reaches the glomerular capillary wall and prevents heparan sulfate degradation, thus allowing reconstruction of heparan sulfate content and restoration of GBM ionic permselectivity. Two clinical trials are currently being carried out to determine whether sulodexide is renoprotective in diabetic nephropathy.
机译:肾小球毛细血管滤膜的理化特性基于分子量,电荷和形状限制大分子的通过。所建议的肾小球基底膜(GBM)的离子电荷渗透选择性特征取决于其化学成分,主要是高度硫酸化的糖胺聚糖乙酰肝素。在糖尿病性肾病中,GBM的硫酸乙酰肝素含量降低。已经提出降低的GBM硫酸乙酰肝素含量引起对带负电荷的大分子如白蛋白的选择性渗透降低,从而使该蛋白泄漏到尿液中。糖尿病性肾病中GBM硫酸乙酰肝素含量降低的一种可能解释是观察到肝素酶是一种能够降解硫酸乙酰肝素的酶,其响应于葡萄糖增加而在肾小球上皮细胞(GEC)中上调。在糖尿病肾的肾小球中已证明GEC乙酰肝素酶活性增加,并且在糖尿病性肾病中观察到尿乙酰肝素酶增加。体外研究表明,GEC乙酰肝素酶活性取决于培养基中的葡萄糖浓度。肝素化合物可抑制GEC乙酰肝素酶活性。舒洛糖胺是一种口服活性的低分子量肝素,已被证明可以降低尿白蛋白排泄。出现的有效假说是舒洛地昔可能是一种体内乙酰肝素酶抑制剂,可到达肾小球毛细血管壁并阻止硫酸乙酰肝素降解,从而可重建硫酸乙酰肝素含量并恢复GBM离子渗透选择性。目前正在进行两项临床试验,以确定舒洛地昔在糖尿病性肾病中是否具有肾脏保护作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号